Xcell Biosciences company logo

The profile is currenly unclaimed by the seller. All information is provided by CB Insights.


Founded Year



Series B | Alive

Total Raised


Last Raised

$27.5M | 1 yr ago

About Xcell Biosciences

Xcell Biosciences develops products and workflows that empower scientists in important fields including cancer research, immunology, stem cell biology, and cell therapy development. The company's advanced primary cell culturing platform, the Avatar system, allows for complete control of key physiological conditions found in cellular microenvironments. The Avatar system empowers researchers and drug developers with new capabilities, including propagation of difficult samples such as tumor biopsies and other primary cell types. The technology also offers dramatic improvements in transfection and gene editing efficiencies in primary cell populations for regenerative medicine and cell-based therapy applications.

Xcell Biosciences Headquarter Location

455 Mission Bay Blvd South Suite 145

San Francisco, California, 94158,

United States


Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Xcell Biosciences

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Xcell Biosciences is included in 2 Expert Collections, including Regenerative Medicine.


Regenerative Medicine

1,818 items

Regenerative medicine refers to the process of activating, replacing, engineering or regenerating human genetic material, cells, tissues or organs to restore normal function. It also includes bioengineered tissues used for in vitro testing (e.g. organ-on-a-chip, organoids).



3,605 items

Companies researching, developing, or offering products & services that aid in the screening, prevention, diagnosis, management, and treatment of cancer.

Xcell Biosciences Patents

Xcell Biosciences has filed 11 patents.

The 3 most popular patent topics include:

  • Transcription factors
  • Clusters of differentiation
  • Cell biology
patents chart

Application Date

Grant Date


Related Topics




Transcription factors, Clusters of differentiation, Cell biology, Biotechnology, Immunology


Application Date


Grant Date



Related Topics

Transcription factors, Clusters of differentiation, Cell biology, Biotechnology, Immunology



Latest Xcell Biosciences News

The Worldwide Formulation Development Outsourcing Industry is Expected to Reach $61.4 Billion by 2030

Jul 20, 2022

The global formulation development outsourcing market size is expected to reach USD 61.4 billion by 2030. The market is expected to expand at a CAGR of 7.2% from 2022 to 2030. The high burden of chronic and infectious diseases, the growing focus on improving the bioavailability of poorly soluble drugs, and the complications associated with drug development are contributing to the demand for formulation development services globally. Furthermore, the COVID-19 outbreak has influenced the need for clinical trials to find an effective treatment against the contagious virus. This has resulted in significant investments in research and development (R&D) to develop therapeutics, which are expected to drive the market. According to Pharma R&D Annual Review 2022, biopharmaceutical and anticancer drugs are the major drugs in the development stage in the year 2022, this is expected to improve the demand for formulation development of these drugs post pandemic. Pharmaceutical companies globally are making significant contributions in R&D activities. For instance, Merck's R&D cost was USD 2,516.8 million in 2020 as compared to USD 2,494.8 million in 2019. Similarly, Biogen's R&D expenses accounted for USD 3,990.9 million in 2020. The company's R&D expenditure increased by 75% as compared to 2019. The significant increase in R&D expenditure is likely to have a positive impact on the market. A significant number of drugs fail to reach late-stage clinical trials owing to complications associated with formulation development. Moreover, strict regulations regarding the development of drugs are further contributing to the demand for outsourcing of formulation development. Such factors are expected to improve the demand for the formulation development outsourcing. The COVID-19 incidence has been significantly reduced owing to the growing vaccination drive globally. As a result, the CRO and CDMO are once again concentrating on the development of drugs for oncology and other disorders. For instance, in April 2022, Labcorp collaborated with Xcell Biosciences in order to support the company in developing cell and gene therapies for treating cancer, Parkinson's disease, and other rare diseases. Such initiatives by the CDMO's are likely to promote the demand for the formulation development outsourcing of drugs used in the treatment of cancer and other rare diseases. Formulation Development Outsourcing Market Report Highlights Based on services, the preformulation segment is expected to witness a CAGR of 6.8% over the forecast period owing to the growing demand for new drugs due to the high disease burden worldwide. Based on formulation, the injectable products segment is expected to rise with a fastest CAGR of 7.8% over the forecast period owing to the high bioavailability of parental formulations. Based on therapeutic area, the oncology segment is likely to witness the fastest CAGR of 8.4% over the forecast owing high burden of cancer worldwide, thus contributing demand for formulation development of new drugs. Asia pacific held the largest revenue share in 2021 due to the presence of significant number of CRO providing cost effective formulation development services. Key Topics Covered: Chapter 2 Executive Summary 3.1 Segment Outlook 3.3 Market Dynamics Complications associated with formulation development Cost effectiveness of formulation outsourcing services 3.3.2 Market Restraint Analysis 3.4 Formulation Development Outsourcing Market Analysis Tools 3.4.1 Porter's Five Forces Analysis 3.4.2 PESTEL Analysis 3.5 COVID-19 Impact Analysis 4.1 Definitions & Scope 4.3 Preformulation 4.4. Formulation Development Chapter 5 Formulation Development Outsourcing Market: Formulation Segment Analysis 5.1 Definition & Scope 5.3 Oral 5.4 InjecTable 5.5. Topical 5.6 Others Chapter 6 Formulation Development Outsourcing Market: Therapeutic Area Segment Analysis 6.1 Definitions & Scope 6.3 Oncology 6.4 Infectious Diseases 6.5 Neurology 6.6 Hemotolgy 6.7 Respiratory 6.8 Cardiovascular 6.9 Dermatology 6.10 Others Chapter 7 Formulation Development Outsourcing Market: Regional Analysis Chapter 8 Company Profiles

Xcell Biosciences Web Traffic

Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Xcell Biosciences Rank

  • When was Xcell Biosciences founded?

    Xcell Biosciences was founded in 2012.

  • Where is Xcell Biosciences's headquarters?

    Xcell Biosciences's headquarters is located at 455 Mission Bay Blvd South, San Francisco.

  • What is Xcell Biosciences's latest funding round?

    Xcell Biosciences's latest funding round is Series B.

  • How much did Xcell Biosciences raise?

    Xcell Biosciences raised a total of $39.62M.

  • Who are the investors of Xcell Biosciences?

    Investors of Xcell Biosciences include HBM Genomics, Casdin Capital, Dynamk Capital, Formic Ventures, LabCorp Venture Fund and 5 more.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.